Reactosome develops a Synthetic Nucleus platform that functions as a programmable molecular compartment for intracellular applications. This system precisely delivers complex genetic cargo and enables localized RNA expression and protein production within the cell. The technology offers a new modality for gene therapies, regenerative medicine, and distributed biomanufacturing.
Funding
Funding not disclosed
Founders
Product
Problem
Current RNA and DNA-based therapies face limitations in cargo capacity and duration of gene expression, while also raising safety concerns due to potential off-target effects and genomic integration. These challenges hinder the effective treatment of complex diseases, including cancer and age-related disorders.
Solution
Reactosome is developing a synthetic nucleus that operates continuously within cells, mimicking the function of a natural nucleus to enhance gene expression. This approach enables safer and more sustained nucleic acid therapies with larger cargo capacity compared to traditional methods. By creating an artificial organelle within the cell, Reactosome aims to overcome the limitations of existing RNA and DNA-based treatments, offering a novel platform for gene therapy. The synthetic nucleus provides a stable environment for gene expression, potentially leading to more effective and durable therapeutic outcomes.
Target Audience
The primary target audience includes researchers and pharmaceutical companies developing gene therapies for complex diseases such as cancer and age-related disorders.
Features
- Synthetic nucleus designed for continuous operation within cells
- Enhanced gene expression compared to RNA-based solutions
- Improved safety profile compared to DNA-based therapies
- Increased cargo capacity for delivering larger genetic payloads
- Mimics the function of a natural nucleus to maintain cellular compatibility